Sanofi Unit Loses Stem Cell Patent Amid Rivals' Protests
Sanofi-owned biotech Genzyme Corp. has lost an amended version of its European patent over a stem cell treatment after a group of its rivals proved that a key pillar of the...To view the full article, register now.
Already a subscriber? Click here to view full article